Amarin Co. plc (NASDAQ:AMRN) – Research analysts at Oppenheimer lowered their FY2021 earnings per share estimates for shares of Amarin in a research note issued to investors on Wednesday, January 22nd. Oppenheimer analyst L. Gershell now anticipates that the biopharmaceutical company will post earnings per share of $0.04 for the year, down from their previous estimate of $0.08. Oppenheimer has a “Sell” rating and a $13.00 price target on the stock. Oppenheimer also issued estimates for Amarin’s FY2022 earnings at $0.56 EPS.
A number of other research firms have also recently weighed in on AMRN. Stifel Nicolaus reaffirmed a “hold” rating on shares of Amarin in a research note on Tuesday, January 7th. HC Wainwright reaffirmed a “buy” rating and set a $51.00 price target on shares of Amarin in a research note on Thursday, January 9th. Citigroup cut shares of Amarin from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 27th. TheStreet raised shares of Amarin from a “d” rating to a “c-” rating in a research note on Friday, November 15th. Finally, BidaskClub cut shares of Amarin from a “hold” rating to a “sell” rating in a research note on Friday, January 10th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and eight have given a buy rating to the company. Amarin currently has an average rating of “Hold” and a consensus target price of $27.62.
NASDAQ:AMRN opened at $20.22 on Thursday. The company has a quick ratio of 3.45, a current ratio of 3.69 and a debt-to-equity ratio of 0.02. Amarin has a fifty-two week low of $13.76 and a fifty-two week high of $26.12. The stock has a market cap of $7.22 billion, a PE ratio of -101.09 and a beta of 1.05. The firm’s fifty day simple moving average is $21.16 and its 200-day simple moving average is $18.40.
Amarin (NASDAQ:AMRN) last announced its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($0.01) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.03. The company had revenue of $112.40 million during the quarter, compared to the consensus estimate of $110.04 million. Amarin had a negative net margin of 17.42% and a negative return on equity of 26.67%. Amarin’s quarterly revenue was up 104.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.08) EPS.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Eqis Capital Management Inc. acquired a new stake in Amarin in the 4th quarter valued at about $2,763,000. Premier Asset Management LLC acquired a new stake in shares of Amarin during the 4th quarter worth about $565,000. Joseph P. Lucia & Associates LLC boosted its stake in shares of Amarin by 25.5% during the 4th quarter. Joseph P. Lucia & Associates LLC now owns 4,080 shares of the biopharmaceutical company’s stock worth $87,000 after purchasing an additional 830 shares during the last quarter. Ambassador Advisors LLC acquired a new stake in shares of Amarin during the 4th quarter worth about $459,000. Finally, DAVENPORT & Co LLC boosted its stake in shares of Amarin by 6.8% during the 4th quarter. DAVENPORT & Co LLC now owns 174,700 shares of the biopharmaceutical company’s stock worth $3,746,000 after purchasing an additional 11,150 shares during the last quarter. 52.77% of the stock is currently owned by hedge funds and other institutional investors.
In related news, Director Lars Ekman sold 38,600 shares of the stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $24.02, for a total value of $927,172.00. Also, CEO John F. Thero sold 475,546 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $24.02, for a total transaction of $11,422,614.92. Over the last three months, insiders sold 788,600 shares of company stock worth $18,088,620. 2.75% of the stock is owned by corporate insiders.
Amarin Company Profile
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.
Further Reading: Diversification in Investing
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.